Anti-inflammatory dose
doxycycline 40 mg capsules (30 mg immediate-release and 10 mg delayed-release beads) provide a sub-antimicrobial dose that reduces the inflammatory response in patients with
rosacea without producing
drug concentrations required to treat
bacterial diseases. The efficacy of oral, anti-inflammatory dose
doxycycline 40 mg capsules once daily in the treatment of adults with
rosacea was demonstrated in two pivotal large, randomized, double-blind, placebo-controlled, multicenter trials. After 16 weeks'
therapy, anti-inflammatory dose
doxycycline 40 mg was significantly more effective in improving
rosacea than placebo, providing a greater reduction in the total inflammatory lesion count (primary endpoint) than placebo. Anti-inflammatory dose
doxycycline 40 mg was associated with a rapid onset of action, achieving a significantly greater decrease in total inflammatory lesion count than placebo by the first follow-up visit at week 3 in both studies. Maximum anti-inflammatory efficacy appears to be achieved with
doxycycline 40 mg capsules once daily, as no additional improvement in
rosacea symptoms was achieved with oral
doxycycline 100 mg once daily (usual antibacterial dosage) in a small, randomized, double-blind trial. Anti-inflammatory dose
doxycycline 40 mg was generally well tolerated in clinical trials, with most adverse events being of mild to moderate intensity.